AUTHORS
Panagiotis Malandrakis, MD, MSc, PhD, Evangelos Terpos, MD2, Ioannis Ntanasis-Stathopoulos, MD3, Charalampos Filippatos4, Ioannis V Kostopoulos, PhD, MSc5, Vasiliki Spiliopoulou6, Evangelos Eleutherakis-Papaiakovou7, Eirini Solia, MD8, Ilias Katsadouros, MD9, Panagiotis Boutsikos, MD10, Magdalini Migkou11, Nikolaos Kanellias, MD, PhD12, Ourania Tsitsilonis, MD,PhD13, Efstathios Kastritis, MD14, Maria Gavriatopoulou, MD15, Meletios-Athanasios (Thanos) C. Dimopoulos, MD16
AFFILIATIONS
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 National and Kapodistrian University of Athens, Athens, Greece
13 National and Kapodistrian University of Athens, Athens, Greece
14 National and Kapodistrian University of Athens, Athens, Greece
15 National and Kapodistrian University of Athens, Athens, Greece
16 National and Kapodistrian University of Athens, Athens, Greece
ABSTRACT
Introduction
Maintenance treatment with lenalidomide after autologous stem cell transplantation (ASCT) is currently administered until disease progression in patients with newly diagnosed multiple myeloma (MM); however, the optimal duration of maintenance is yet to be defined. Based on the recently published data from the ENDURANCE trial, indefinite maintenance is not definitely superior to a fixed duration of therapy for patients with standard risk disease.
Methods
In this prospective study, we included patients with newly diagnosed MM from January 1st, 2016 to December 31st, 2021, who underwent ASCT followed by lenalidomide maintenance. Minimal residual disease (MRD) status was assessed in patients who had achieved complete response (CR) or stringent CR (sCR) and then at 6, 12, 24, and 36 months after the initiation of lenalidomide maintenance. MRD samples were evaluated by next generation flow, according to the EuroFlow protocol. Patients, who had at least 3 consecutive MRD negative results and had received at least 3 years of maintenance therapy, underwent a PET/CT scan. If patients had achieved imaging MRD negativity, they discontinued lenalidomide maintenance; MRD was performed every 6 months and PET-CT every year, thereafter. If a patient converted from MRD negative to positive or if the patient relapsed from CR, lenalidomide maintenance was restarted at the same dose level. The co-primary endpoints of the study were the rate of MRD conversion from MRD negative to MRD positive after the discontinuation of lenalidomide and the treatment-free survival (TFS) among the MM patients who discontinued maintenance.
Results
Overall, 194 patients received induction with proteasome inhibitor-based regimens (VCD, VRD or VTD) and underwent ASCT. During the follow-up period, 54 (27.8%) patients achieved 3-year sustained bone marrow MRD negativity and imaging MRD negativity after maintenance initiation. Thus, they discontinued lenalidomide maintenance, according to study schedule. Their median age at MM diagnosis was 56 years (range 39-66). Twenty-nine (53.7%) patients were males. The patient distribution per ISS was ISS 1 59.2%, ISS 2 35.2% and ISS 3 5.6%, whereas per R-ISS only 5.9% were classified as RISS-3. In this subgroup of the patients, 27.8% had at least one high risk cytogenetic risk factor (1q21 addition or amplification, t(4;14), t(14;16) and del17p/tp53 loss). According to IMS/IMWG CGS, 14 patients had high risk and 40 had standard risk myeloma. 24.4% received 2 cycles of consolidation post ASCT with the same as the induction regimen.
The median follow-up time from maintenance discontinuation for these patients was 55 months (95% CI: 53.3-59.6). Regarding the primary endpoint, 18/54 (33.3%) patients developed MRD positivity and restarted lenalidomide monotherapy according to the protocol, after a median of 30.6 months (range 1.3 – 56.8). Six (33.3%) out of these 18 patients progressed and received second-line treatment, despite lenalidomide reinitiation, and one patient died due a second primary malignancy. Only one patient reconverted from MRD positive to negative. Among those 18 patients who converted from MRD negative to positive, 8/14 (57.1%) had high risk myeloma per IMS/IMWG CGS, and 10/40 (25%) had standard risk disease. The median follow-up time from the reinitiation of lenalidomide was 22.3 months (range, 0.5-59 months). The 3-, 4- and 5-year PFS from lenalidomide discontinuation were 90.4%, 87.9% and 87.9% respectively. The 3-, 4- and 5-year TFS were 74.5%, 67.6% and 56.4%, respectively. Potential covariates of age, gender, R2-ISS and consolidation therapy did not affect TFS and PFS at a statistically significant level in a cox regression model.
Conclusions
Sustained MRD negativity after ASCT and 3 years lenalidomide maintenance can lead to safe maintenance discontinuation in standard risk patients, although this has to be proven in prospective randomized clinical trials. High risk patients are not recommended to stop maintenance with lenalidomide even after 3-year sustained MRD negativity. Close surveillance with longitudinal MRD testing can identify those patients who may develop myeloma relapse. Lenalidomide reinitiation in MRD positive patients does not seem to ultimately defer disease progression.
DISCLOSURES
Panagiotis Malandrakis, MD, MSc, PhD: No relevant conflicts of interest to declare.